🇺🇸 FDA
Pipeline program

124I-labeled monoclonal antibody Mu 11-1F4

2625A

Phase 1 mab completed

Quick answer

124I-labeled monoclonal antibody Mu 11-1F4 for AL Amyloidosis is a Phase 1 program (mab) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
AL Amyloidosis
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials